武汉禾元生物研发投产 “稻米造血”新药在全国多家医院投用

Group 1 - The core innovation of "rice-derived" recombinant human albumin injection is now in use across multiple hospitals in China, with dozens of patients already treated [1] - Recombinant human albumin is crucial for treating conditions like liver cirrhosis and is traditionally sourced from human plasma, which is limited and over 60% of it is imported in China [1] - The new "rice-derived" method involves inserting the human albumin gene into rice, allowing the plant to produce albumin, which is then extracted and purified, achieving a purity of 99.9999% [1][2] Group 2 - The research on recombinant human albumin began in the 1980s, but previous attempts to produce it in various organisms faced challenges such as low yield and high purity requirements [2] - The founder of He Yuan Biotechnology, Yang Daichang, successfully increased the expression level of recombinant human albumin in rice to 30 grams per kilogram, overcoming production bottlenecks [2] - He Yuan Biotechnology has received a production license for its 1 million unit commercial production line, with a factory set to produce 12 million units annually by 2026, marking a significant advancement in China's capabilities in this field [2]